Levey AS, Coresh J. Chronic kidney disease. Lancet. 2012;379:165–80.
Selvarajah S, Uiterwaal CS, Haniff J, van der Graaf Y, Visseren FL, Bots ML, et al. Renal impairment and all-cause mortality in cardiovascular disease: effect modification by type 2 diabetes mellitus. Eur J Clin Investig. 2013;43:198–207.
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.
McCullough PA. Cardiovascular disease in chronic kidney disease from a cardiologist’s perspective. Curr Opin Nephrol Hypertens. 2004;13:591–600.
Herzog CA, Asinger RW, Berger AK, Charytan DM, Diez J, Hart RG, et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011;80:572–86.
Liu PP. Cardiorenal syndrome in heart failure: a cardiologist's perspective. Can J Cardiol. 2008;24(Suppl B):25B–9.
Hernandez-Resendiz S, Correa F, Garcia-Nino WR, Buelna-Chontal M, Roldan FJ, Ramirez-Camacho I, Delgado-Toral C, Carbo R, Pedraza-Chaverri J, Tapia E, Zazueta C. Cardioprotection by curcumin post-treatment in rats with established chronic kidney disease. Cardiovasc Drugs Ther. 2015;29: this issue.
Correa F, Buelna-Chontal M, Hernández-Reséndiz S, García-Niño WR, Roldán FJ, Soto V, et al. Curcumin maintains cardiac and mitochondrial function in chronic kidney disease. Free Radic Biol Med. 2013;61:119–29.
Gupta SC, Prasad S, Kim JH, Patchva S, Webb LJ, Priyadarsini IK, et al. Multitargeting by curcumin as revealed by molecular interaction studies. Nat Prod Rep. 2011;28:1937–55.
Akbik D, Ghadiri M, Chrzanowski W, Rohanizadeh R. Curcumin as a wound healing agent. Life Sci. 2014;116:1–7.
Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as “Curecumin”: from kitchen to clinic. Biochem Pharmacol. 2008;75:787–809.
Prasad S, Gupta SC, Tyagi AK, Aggarwal BB. Curcumin, a component of golden spice: from bedside to bench and back. Biotechnol Adv. 2014;32:1053–64.
Tapia E, Soto V, Ortiz-Vega KM, Zarco-Marquez G, Molina-Jijon E, Cristobal-Garcia M, et al. Curcumin induces Nrf2 nuclear translocation and prevents glomerular hypertension, hyperfiltration, oxidant stress, and the decrease in antioxidant enzymes in 5/6 nephrectomized rats. Oxid Med Cell Longev. 2012;2012:269039.
Dyer JL, Khan SZ, Bilmen JG, Hawtin SR, Wheatley M, Javed MU, et al. Curcumin: a new cell-permeant inhibitor of the inositol 1,4,5-trisphosphate receptor. Cell Calcium. 2002;31:45–52.
Yamda J, Ohkusa T, Nao T, Ueyama T, Yano M, Kobayashi S, et al. Up-regulation of inositol 1,4,5 trisphosphate receptor expression in atrial tissue in patients with chronic atrial fibrillation. J Am Coll Cardiol. 2001;37:1111–9.
Arantes LA, Aguiar CJ, Amaya MJ, Figueiro NC, Andrade LM, Rocha-Resende C, et al. Nuclear inositol 1,4,5-trisphosphate is a necessary and conserved signal for the induction of both pathological and physiological cardiomyocyte hypertrophy. J Mol Cell Cardiol. 2012;53:475–86.
Yoo SH. Chromogranins and inositol 1,4,5-trisphosphate-dependent Ca(2+)-signaling in cardiomyopathy and heart failure. Curr Med Chem. 2012;19:4068–73.
Ghosh SS, Salloum FN, Abbate A, Krieg R, Sica DA, Gehr TW, et al. Curcumin prevents cardiac remodeling secondary to chronic renal failure through deactivation of hypertrophic signaling in rats. Am J Physiol Heart Circ Physiol. 2010;299:H975–84.
Zeng C, Zhong P, Zhao Y, Kanchana K, Zhang Y, Khan ZA, et al. Curcumin protects hearts from FFA-induced injury by activating Nrf2 and inactivating NF-kappaB both in vitro and in vivo. J Mol Cell Cardiol. 2015;79:1–12.
Ma Q. Role of nrf2 in oxidative stress and toxicity. Ann Rev Pharmacol Toxicol. 2013;53:401–26.